Labiotech.eu

Pfizer’s strategy: how the company is evolving after its COVID success

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.
Seeking Alpha

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...
Seeking Alpha

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Yahoo

Pfizer, BioNTech showcase new data supporting COVID booster

Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.
Hosted on MSN

Pfizer is said to divest remaining stake in BioNTech

BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...